Skip Navigation LinksHome > October 2011 - Volume 30 - Issue 10 > Combined Use of Subconjunctival and Intracorneal Bevacizumab...
Cornea:
doi: 10.1097/ICO.0b013e31821379aa
Clinical Science

Combined Use of Subconjunctival and Intracorneal Bevacizumab Injection for Corneal Neovascularization

Yeung, Sonia N MD, PhD, FRCSC; Lichtinger, Alejandro MD; Kim, Peter MBBS(Hons), FRANZCO; Amiran, Maoz D MD; Slomovic, Allan R MA, MD, FRCSC

Collapse Box

Abstract

Purpose: To report on the safety and clinical use of combined subconjunctival and intracorneal bevacizumab for corneal neovascularization.

Methods: The charts of 12 consecutive patients with corneal neovascularization who received combined subconjunctival and intracorneal injections of bevacizumab (2.5 mg/0.1 mL) were reviewed. Patients received 1 to 3 injections of 2.5 mg of bevacizumab (1.25 mg/0.05 mL subconjunctival and 1.25 mg/0.05 mL intrastromal). Morphological changes were assessed clinically by 1 investigator.

Results: Combined subconjunctival and intracorneal injections of bevacizumab were effective and well-tolerated. No significant ocular or systemic adverse events were observed during 6.4 months (range, 0.25-22 months) of follow-up. All patients showed a reduction in the neovascularized area.

Conclusions: Short-term results suggest that combined subconjunctival and intracorneal injections of bevacizumab are an effective method for reducing corneal neovascularization. It may be a useful option or adjunct to other treatments in stabilizing or improving vision.

© 2011 Lippincott Williams & Wilkins, Inc.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.